Author + information
- Received January 24, 2019
- Accepted February 4, 2019
- Published online April 29, 2019.
- Salim S. Hayek, MDa,
- Sarju Ganatra, MDb,
- Carrie Lenneman, MD, MSCIc,
- Marielle Scherrer-Crosbie, MD, PhDd,
- Monika Leja, MDa,
- Daniel J. Lenihan, MDe,
- Eric Yang, MDf,
- Thomas D. Ryan, MD, PhDg,
- Jennifer Liu, MDh,
- Joseph Carver, MDi,
- Negareh Mousavi, MDj,
- Rupal O’Quinn, MDd,
- Anita Arnold, DOk,
- Jose Banchs, MDl,
- Ana Barac, MD, PhDm,∗∗ (, )@AnaBaracCardio and
- Bonnie Ky, MD, MSCEn,∗∗∗ ()
- aDivision of Cardiology, University of Michigan, Ann Arbor, Michigan
- bLahey Hospital and Medical Center, Burlington, Massachusetts
- cDivision of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, Alabama
- dDivision of Cardiology, University of Pennsylvania, Philadelphia, Pennsylvania
- eDivision of Cardiology, Cardio-Oncology Center of Excellence, Washington University in St. Louis, St. Louis, Missouri
- fDivision of Cardiology, University of California at Los Angeles, Los Angeles, California
- gDepartment of Pediatrics, University College of Medicine and Heart Institute, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio
- hMemorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, New York, New York
- iDivision of Cardiology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania
- jDivision of Cardiology, McGill University, Montreal, Quebec, Canada
- kDivision of Cardiology, Florida State University, Tallahassee, Florida
- lDivision of Cardiology, MD Anderson Cancer Center, Houston, Texas
- mMedStar Heart and Vascular Institute, Washington, DC
- nDepartment of Epidemiology, Biostatistics and Informatics, University of Pennsylvania, Philadelphia, Pennsylvania
- ↵∗Address for correspondence:
Dr. Ana Barac, Medstar Heart and Vascular Institute, 110 Irving Street, NW, Suite 1F1218, Washington, DC 20010.
- ↵∗∗Dr. Bonnie Ky, Perelman School of Medicine at the University of Pennsylvania, Smilow Center for Translational Research, 3400 Spruce Street, 11-105, Philadelphia, Pennsylvania 19104.
• Cardio-oncology has emerged as a discipline and subspecialty in response to the rapidly growing number of patients with cancer at risk of, or with comorbid cardiovascular disease.
• Specialists in cardio-oncology are involved in all aspects of the care of cancer patients: from informing pre-treatment risk and regimen selection, addressing the complex cardiovascular adverse effects of cancer therapy, and mitigating the heightened long-term risks of cardiovascular disease in survivorship.
• Centers offering cardio-oncology services have doubled in number since 2014, and close to one-half of cardiovascular training programs incorporate cardio-oncology topics in their core curriculum.
• The future of the discipline is dependent on the collaboration with oncology and defining competencies around which an effective training structure for providers can be built.
Cardiovascular disease and cancer are the 2 main causes of death in the United States. They intersect on multiple levels, sharing common causal mechanisms and epidemiological risk factors. The growing prevalence and complexity of cardiovascular disease and cancer have resulted in the development of the discipline of cardio-oncology. Preparing the cardiovascular workforce for the care of a growing population of cancer patients is necessary to enhance the delivery of high-quality cardiovascular care for patients with cancer. The goal of this review is to present the dedicated efforts of the cardio-oncology community to meet the growing need for education and training of cardiovascular practitioners providing care to cancer patients and survivors. Integration in general cardiology training programs and the efforts of the stakeholder organizations serve as an example of how a multidimensional, innovative approach can address provider education and training needs in a relatively new discipline.
↵∗ Drs. Barac and Ky have contributed equally to this work and are cosenior authors.
Dr. Barac has received research support from Genentech; and has served on the Speakers Bureau for Bristol-Myers Squibb. Dr. Ky was supported in part by National Cancer Institute grant number UG1CA189828; and has received research support from Genentech. Dr. Lenihan has been a consultant to Roche, Pfizer, Bristol-Myers Squibb, Prothena, and Boehringer Ingelheim. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Received January 24, 2019.
- Accepted February 4, 2019.
- 2019 American College of Cardiology Foundation
This article requires a subscription or purchase to view the full text. If you are a subscriber or member, click Login or the Subscribe link (top menu above) to access this article.